Details of the Drug

General Information of Drug (ID: DMQI970)

Drug Name
Lumoxiti
Synonyms Moxetumumab pasudotox-tdfk
Indication
Disease Entry ICD 11 Status REF
Hairy cell leukaemia 2A82.2 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DNML54

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hairy cell leukaemia
ICD Disease Classification 2A82.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03805932) Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Innate Pharma.